A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes

NCT01496495 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: ARRY-614, p38/Tie2 inhibitor; oral

Sponsor

Array Biopharma, now a wholly owned subsidiary of Pfizer